Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Items 601–700 of 765
Vector Systems for Prenatal Gene Therapy: Choosing Vectors for Different Applications
Coutelle, C., & Waddington, S. N. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-873-3_3 · Cited by 4
The Interactions between Cells and Viruses
Fujimuro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136886 · Cited by 5
“However, host immune responses to the vector have meant that some hurdles remain for the successful implementation of rAAV-based gene transfer [31,32].”
BackgroundMatsushima, S. K., Shimada, Y., Kinoshita, M., Nagashima, T., Okamoto, S., Iizuka, S., Takagi, H., Iizuka, S., Higuchi, T., Hioki, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci180724 · Cited by 3
Thakur, G., Mink, S. R., Bak, H., & Tustian, A. D. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.70021 · Cited by 3
Reduced rAAV interference enhances rcAAV detection sensitivity
Yang, M., Shaheen, S., Yang, K., Gao, X., Wu, K., Zhu, X., Kang, Q., Wang, L., Hemmatzadeh, F., Zheng, Q., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101584 · Cited by 3
The hepatic Odyssey of Adeno-associated virus: from gene delivery to long-term outcomes
Simini, G., & Batty, P. A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.028 · Cited by 3
Artemyev, V., Paremskaia, A. I., Dzhioeva, A. A., Mishina, D., Bogdanov, V. P., Krupinova, J. A., Mazloum, A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2025) · Cells · doi:10.3390/cells15010014 · Cited by 4
Immunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 6
“Destruction of hepatic cells has led to elevations of liver transaminase activities posing safety concerns for liver-targeted gene therapies [22].”
Fong, S., Swystun, L. L., Batty, P. A., & Lillicrap, D. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207251406537 · Cited by 3
“79,81 15 In contrast, one phase I/II study (B-AMAZE) reported supraphysiological peak FIX levels (FIX:C > 150 IU/dL) in patients treated at a dose of 8.32 × 10 11 with a more marked decline in the first year after completion of prophylactic immune suppression compared to those treated at lower…”
InfluentialTissue‐specific gene delivery approaches
Nasr, S. S., Cheema, Y., Stern, A., Tabah, O., Poore, S., & Duncan, G. A. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70125 · Cited by 4
Hajjar, R. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381510-1.00046-6 · Cited by 3
AAV vectors for long-term gene therapy of hemophilia B: Are we there yet?
Srivastava, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.009 · Cited by 3
Hitting the Target Without Pulling the Trigger
VandenDriessche, T., & Chuah, M. (2015) · Molecular Therapy · doi:10.1038/mt.2014.230 · Cited by 3
Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders
Odiba, A. S., Okoro, N. O., Durojaye, O. A., & Wu, Y. (2021) · Open Life Sciences · doi:10.1515/biol-2021-0033 · Cited by 3
“By using AAV vectors in vivo, molecular gene transfer through the hepatic artery of the liver can correct hemophilia B (FIX deficiency) and is considered an ideal strategy as demonstrated in preclinical studies [61,62].”
Gene Therapy in Hemophilia: Latest Developments
Sanchez-Lara, P. A., Nathanson, J., & Valentino, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-93990-8_18 · Cited by 4
AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
Jacobs, R., Dogbey, D. M., Mnyandu, N., Neves, K., Barth, S., Arbuthnot, P. B., & Maepa, M. B. (2023) · Microorganisms · doi:10.3390/microorganisms11122985 · Cited by 3
“An increase in AAV-specific memory CD8 + T cells and diminished transgene expression were detected 4 weeks after infection with Factor IX-expressing AAVs in hemophilia B trials [128,129].”
BackgroundRecent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections
Mnyandu, N., Jacobs, R., Arbuthnot, P. B., & Maepa, M. B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111360 · Cited by 3
Safety of Adeno-Associated Viral Vectors
Lin, S., & Ertl, H. C. J. (2008) · Future Virology · doi:10.2217/17460794.3.5.491 · Cited by 3
“IX expression in animal models and it was concluded that, unlike animals, humans have pre-existing memory CD8+ T cells against the antigens of AAV capsid, which became activated upon gene transfer and eliminated the transduced hepatocytes [111].”
BackgroundResultSelf-citationPreclinical Study Design for rAAV
Flotte, T. R., Conlon, T. J., & Mueller, C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_14 · Cited by 3
6. Themenbereich somatische Gentherapie: Translationale und klinische Forschung
Fehse, B., & Domasch, S. (2015) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783845246956-210 · Cited by 5
AAV Capsid Engineering: Zooming in on the Target
VandenDriessche, T. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.29042.tva · Cited by 4
“Diminishing inadvertent gene transfer in hepatocytes with AAV2i8 constitutes an important step toward optimizing the target cell specificity of AAV vectors and may reduce the risk of hepatotoxicity associated with AAV-specific inflammatory immune responses.(4,5) Compared with AAV9, the AAV2i8 vector unexpectedly resul…”
BackgroundAdeno-Associated Virus and AAV Vectors for Gene Delivery
Carter, B. (2015) · CRC Press eBooks · doi:10.1201/b18002-6 · Cited by 3
The role and mechanism of RLR innate immune signaling pathway in long-term AAV infection
Wang, Y., Pei, X., Huang, W., Sima, H., Yang, Y., Xu, X., Yang, X., Ren, C., Zhang, L., & Shao, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114267 · Cited by 2
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
Re-administration of AAV-mediated gene therapy for OTOF-related deafness: a single-arm trial
Fan, X., Zhang, L., Gao, Z., Han, L., Yang, P., Wang, D., Yu, H., Cao, Q., Jiang, L., Chen, X., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04505-4 · Cited by 2
“All AEs deemed possibly or definitely treatment After re-administration, anti-AAV1 NAbs increased 9-fold to 81-fold from baseline to week 6, then declined, beginning at week 13 (Extended Data Table 3).”
InfluentialUpregulation of CD8+ regulatory T cells following liver-directed AAV gene therapy
Gaddie, C. D., Senior, K. G., Chan, C. T., Hoffman, B. E., & Keeler, G. D. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104806 · Cited by 2
Holtkamp, S., Lagoda, F. R., Lister, A., Harish, P., Kleymann, U., Pesch, T., Soon, C. F., Pirmohamed, M., Naisbitt, D. J., & Trautwein, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450524 · Cited by 3
Russell, S. J., & Peng, K. W. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50097-4 · Cited by 2
Gene Therapy for Von Willebrand Disease
Chuah, M., Petrus, I., & VandenDriessche, T. (2011) · Wiley eBooks · doi:10.1002/9781444329926.ch20 · Cited by 2
Platelet‐directed gene therapy overcomes inhibitory antibodies to factor VIII
Chuah, M., & VandenDriessche, T. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04794.x · Cited by 2
Microneedles for Gene Therapy: Overcoming Extracellular and Intracellular Barriers
Cole, G., Dunne, N., & McCarthy, H. O. (2018) · Wiley eBooks · doi:10.1002/9781119305101.ch5 · Cited by 3
Helper-Dependent Adenoviral Vectors for Gene Therapy
Brunetti‐Pierri, N., & Ng, P. (2015) · CRC Press eBooks · doi:10.1201/b18002-5 · Cited by 2
González‐Aseguinolaza, G., & Prìeto, J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.016 · Cited by 3
Royal gene therapy at a royal cost
Ragni, M. V. (2021) · Blood · doi:10.1182/blood.2021012129 · Cited by 2
Self-citationKrivoshik, S. R., Dzielak, L., Masters, A. R., Hall, J. L., & Johnson, A. J. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.180 · Cited by 1
Agbim, C., Wu, H., Kim, C. J., Mutter‐Rottmayer, E., Sadekar, S., & Marković, M. (2025) · Clinical and Translational Science · doi:10.1111/cts.70428 · Cited by 1
“Cellular immunogenicity, and particularly CD8+ T cell responses, have been attributed to the cytotoxicity of transduced cells, leading to durability loss in clinical trials [83, 88] and safety concerns [89].”
Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies
Song, X., Ding, B., Jia, H., & Zhou, H. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101356 · Cited by 2
Selectivity for full AAV capsids in affinity capture with camelid ligands
Bongers, L., Franken, L. E., Hoch, D. K., Huber, V. E., Öttl, V., Raaf, E. B., Hubbuch, J. J., Falkenstein, R., & Martínez, A. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466644 · Cited by 2
Käyhty, P., Nieminen, T., Eriksson, R. A. E., Tumelius, R., Tawfek, A., Laidinen, S., Ruotsalainen, A., Bailey, A., Galibert, L., Lesch, H. P., et al. (2026) · Gene Therapy · doi:10.1038/s41434-025-00588-9 · Cited by 1
“Immune responses against capsid-derived antigens can lead to reduced transgene expression and limit sustained therapeutic bene fi t, particularly when transduced cells are targeted by cytotoxic T cells [3, 8, 12 – 15].”
Ren, D., Chauveau, G. A., Cabon, E., Vendomèle, J., Vignal‐Clermont, C., Saliba, H., Ail, D., Dalkara, D., & Fisson, S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101443 · Cited by 1
Xicluna, R., Yamada, K., Gonzalez-Visiedo, M., Greenwood, C. M., Zaugg, D., Waiz, D., Steiner, G., Hahn, K., Schwandt, T., Otteneder, M. B., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.014 · Cited by 2
Advances in pharmacological treatment for congenital adrenal hyperplasia
Graves, L. E., & Falhammar, H. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001583 · Cited by 2
Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD
Samelson‐Jones, B. J., Martos-Rus, C., Yrigollen, C. M., Tecedor, L., Small, J. C., Matesanz, S. E., Watson, C. T., Heuvel, A. R. V., Carrig, S., Yum, S. W., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2518477 · Cited by 1
Evaluating cases of possible insertional mutagenesis after AAV gene therapy
George, L. A., Ahrens‐Nicklas, R. C., & Bushman, F. D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.026 · Cited by 1
VandenDriessche, T. (2008) · Blood · doi:10.1182/blood-2008-09-177220 · Cited by 1
Will gene therapy trump factor treatment in hemophilia?
Rangarajan, S., & Aledort, L. M. (2013) · Expert Review of Hematology · doi:10.1586/ehm.12.70 · Cited by 1
Dolan, G. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12924 · Cited by 1
Can Viruses be Modified to Achieve Sustained Gene Transfer
Li, H., & Ertl, H. C. J. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00152 · Cited by 1
Self-citationGene- and Cell-Based Therapy for Cardiovascular Disease
Marín-García, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404599-6.00023-8 · Cited by 3
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Self-citationCarlon, M. S., Vidović, D., Dooley, J., da Cunha, M. G. M. C. M., Maris, M., Lampi, Y., Toelen, J., den Haute, C. V., Baekelandt, V., Deprest, J. A., et al. (2013) · Human Gene Therapy · Cited by 2
Recent progress in gene therapies for mucopolysaccharidoses
Ginocchio, V. M., & Brunetti‐Pierri, N. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1529564 · Cited by 1
Gene Replacement Therapy for Duchenne Muscular Dystrophy
Hollinger, K., Crudele, J. M., & Chamberlain, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_18 · Cited by 1
State of the art on clinical trials of gene therapy in haemophilia
Garagiola, I., & Peyvandi, F. (2020) · doi:10.36118/pharmadvances.03.2020.05 · Cited by 1
“ably due to an immune response to the AAV capsid (30).”
BackgroundImmunogenicity of AAV Gene Therapy Products
Jawa, V., & Wu, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch5 · Cited by 1
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond
Ozelo, M. C. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00046-2 · Cited by 1
Clark, R. D. E., Rabito, F., Munyonho, F. T., Remcho, T. P., & Kolls, J. K. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101286 · Cited by 2
Technologies for In Utero Stem Cell Targeting
Borges, B., Lum, T., & MacKenzie, T. C. (2025) · Current Stem Cell Reports · doi:10.1007/s40778-025-00243-4 · Cited by 1
Gaston, C., Fayard, A., Dufour, N., Hantraye, P., Badin, R. A., & Bemelmans, A. (2025) · Revue de primatologie · doi:10.4000/15jub · Cited by 1
The State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
Emerging role of small ribonucleic acids in gastrointestinal tumors
Shapira, I., Sultan, K. S., Mehrotra, B., & Budman, D. R. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.013 · Cited by 1
Kohn, D. B., Carter, B. J., Grandi, P., & Glorioso, J. C. (2009) · Wiley eBooks · doi:10.1128/9781555815981.ch16 · Cited by 1
Access denied : A closer look at anti-phage defense mechanisms
Vlot, M. (2018) · doi:10.18174/449991 · Cited by 1
Gong, H., Yuan, N., Shen, Z., Tang, C., Shipp, S. D., Qian, L., Lu, Y., Andolina, I. M., Zhang, S., Wu, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.08.139667 · Cited by 1
“However, this route requires substantially high vector load, and faces the challenge of natural immunity (Mingozzi et al., 2007).”
BackgroundBello, A. J. A. (2014) · Mspace (University of Manitoba) · Cited by 1
Induction of Immunological Tolerance to Transgene Products
Sack, B. K., Markusic, D. M., & Herzog, R. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5480-9_15
Improving lentiviral vector-mediated gene transfer by understanding cellular barriers
Oakland, M., McCray, P. B., Maury, W. J., Davidson, B. L., Klingelhutz, A. J., & Perlman, S. M. (2013) · doi:10.17077/etd.f63i1jvz
Philippe, S. (2007) · HAL · Cited by 2
Belhoul‐Fakir, H. (2014) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17008231.v1
“…has been observed in some clinical trials (McPhee et al., 2006; Mano et al., 2006), but several strategies have been considered to evade the host immune response such as transient immunosuppression (Mingozzi et al., 2007), in which AAV vector delivery is coupled with an immunosuppressive agent.”
BackgroundGene Therapy Trials in Hemophilia A and B
High, K. A. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch41
Self-citationCLINICAL DEVELOPMENT OF AAV VECTORS
Carter, B. J. (2010) · Gene Therapy and Regulation · doi:10.1142/s1568558610000215
Hollinger, K. (2014) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-3711
“Not only the transgene but also the viral vector can provoke an immune response to AAV in patients (Mendell et al., 2010b, Mingozzi et al., 2007), which interferes with transgene expression.”
Ramakrishnan, V. M. (2015) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2319
[Cellular immunotoxicity of rAAV gene medicine and possible solutions].
Diao, Y., Qizhao, W., Xiao, W., & Xu, R. (2010) · PubMed
Cardiovascular Gene and Cell Therapy
Oka, K. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch35
Ghenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
“Il faut tout d’abord noter que du fait du fort degré de conservation de la séquence en acides aminés de la capside de l’AAV (Gao et al., 2002), les cellules T affichent une forte capacité de réaction croisée de leurs réponses contre la plupart des sérotypes (Mingozzi et al., 2007).”
BackgroundVirus-mediated Delivery of the Fmr1 Gene as a Tool for the Treatment of Fragile X Syndrome
Moghaddam, S. G. (2016) · TSpace (University of Toronto)
Développement d'une stratégie thérapeutique pour la dystrophie facio-scapulo-humérale
Marsollier, A.-C. (2017) · theses.fr (ABES) · doi:10.70675/db3e6e8az7f76z4146zb1f6z8b0c0cd3ad43
Photo-translocation of antiretroviral drugs into HIV-1 permissive cell lines
Khanyile, T. (2015)
Gene Therapy Trials in Hemophilia A and B
High, K. A., & Wright, J. F. (2010) · Wiley eBooks · doi:10.1002/9781444318555.ch36
Self-citationEvolution of Synthetic Nucleocapsids Encapsulating their own RNA genome
Butterfield, G. L. (2018) · ResearchWorks at the University of Washington (University of Washington)
Xiao, P. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rn9x-xq74
Nicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
Nanofabrication and Engineering of Gene Delivery Vectors
Butterworth, E. (2019)
Optimisation of lentiviral vectors for gene therapy of spinal muscular atrophy
Nafchi, N. A. M. (2017)
Genome-Driven Targeted Cancer Therapy
Ferdosi, S. R. (2017) · doi:10.13140/rg.2.2.19842.99527
Gene Therapy for Retinal Disease
McClements, M. E., & MacLaren, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00011-7 · Cited by 1
FIXing Hemophilia B: Sustained Factor IX Expression of 30 Percent After Gene Therapy
George, L. A., & Cuker, A. C. (2016) · The Hematologist · doi:10.1182/hem.v13.5.5951 · Cited by 1
Design of Caspase and MMP-Activatable Adeno-Associated Virus Vectors and Their In Vivo Application
Brun, M. J. (2020) · Rice Research Repository (Rice University)
Ciências da saúde: ensino, formação e pesquisa
Santos, Y. D. S. (2021) · Amplla Editora eBooks · doi:10.51859/amplla.cse238.1121-0
マルチトーン信号のピーク対平均電力比(PAPR)を低減する初期位相設定法
楢橋, 祥., & 野島, 俊. (1995) · Cited by 3
Luzzatto, L. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13409045.15186056
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Self-citationDNA Repair Pathways in the Context of Therapeutic Genome Editing
Wimberger, S., Akrap, N., & Taheri‐Ghahfarokhi, A. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch13
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.